ClinicalTrials.Veeva

Menu

Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Completed

Conditions

Childhood Cancer Survivors Treated With Abdominal Radiation

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to better understand the risk factors and causes of diabetes in people who received radiation to the abdomen as children. The investigators hope this information will allow them to improve how they screen people at risk for diabetes and how they treat patients in the future.

Enrollment

42 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of childhood cancer between 0-21 years of age
  • Prior treatment with abdominal radiation at MSKCC
  • Two or more years from completion of therapy
  • Records of cancer diagnosis and treatment (including radiation records) available

Exclusion criteria

  • Known diagnosis of diabetes
  • Previous treatment with any radiation impacting the brain (cranial radiation, craniospinal radiation, total body irradiation)
  • Neurocognitive deficits that impair ability to give informed consent or assent
  • Patients predicted to have difficult intravenous access, who will likely require multiple venipuncture attempts

Trial design

42 participants in 2 patient groups

treated < 20 years prior to study enrollment
Description:
The following information will be gathered: A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load. C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c. All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated.
treated ≥ 20 years prior to study enrollment
Description:
The following information will be gathered: A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load. C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c. All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems